Emory Genetics Laboratory, a prominent entity in the field of genetic testing, is headquartered in the United States. Established in 1997, the laboratory has made significant strides in advancing genetic diagnostics and personalised medicine. With a focus on clinical genetics, the laboratory offers a comprehensive range of services, including carrier screening, prenatal testing, and hereditary cancer testing, distinguished by their commitment to accuracy and innovation. Operating primarily in the US, Emory Genetics Laboratory has garnered a reputation for excellence, supported by its affiliation with Emory University. The laboratory's unique approach combines cutting-edge technology with expert interpretation, ensuring that healthcare providers receive reliable results. Recognised for its contributions to the genetics industry, Emory Genetics Laboratory continues to lead in research and clinical applications, solidifying its position as a trusted partner in genetic healthcare.
How does Emory Genetics Laboratory's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Emory Genetics Laboratory's score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Emory Genetics Laboratory, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The laboratory is a current subsidiary of Eurofins Scientific SE, which may influence its climate commitments and reporting practices. While there are no documented reduction targets or specific climate pledges from Emory Genetics Laboratory, it is important to note that any climate initiatives or targets may be inherited from its parent company, Eurofins Scientific SE. This includes potential commitments to the Science Based Targets initiative (SBTi) and other sustainability frameworks, although specific details on these initiatives are not provided. As a part of the broader industry context, Emory Genetics Laboratory is expected to align with the sustainability goals set forth by Eurofins Scientific SE, which may include efforts to reduce emissions and enhance environmental performance. However, without specific data or targets, the laboratory's individual climate commitments remain unclear.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 72,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 155,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 311,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Emory Genetics Laboratory has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.